Design Therapeutics Inc. (DSGN)
Design Therapeutics Statistics
Share Statistics
Design Therapeutics has 56.76M shares outstanding. The number of shares has increased by 0.47% in one year.
| Shares Outstanding | 56.76M |
| Shares Change (YoY) | 0.47% |
| Shares Change (QoQ) | 0.25% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 30.87M |
| Failed to Deliver (FTD) Shares | 84 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 3.1M, so 5.48% of the outstanding shares have been sold short.
| Short Interest | 3.1M |
| Short % of Shares Out | 5.48% |
| Short % of Float | 9.87% |
| Short Ratio (days to cover) | 14.25 |
Valuation Ratios
The PE ratio is -7.04 and the forward PE ratio is -4.13. Design Therapeutics's PEG ratio is 0.27.
| PE Ratio | -7.04 |
| Forward PE | -4.13 |
| PS Ratio | 0 |
| Forward PS | 4 |
| PB Ratio | 1.44 |
| P/FCF Ratio | -8.04 |
| PEG Ratio | 0.27 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Design Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.31, with a Debt / Equity ratio of 0.01.
| Current Ratio | 29.31 |
| Quick Ratio | 29.31 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-918.3K |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 2.7% in the last 52 weeks. The beta is 1.78, so Design Therapeutics's price volatility has been higher than the market average.
| Beta | 1.78 |
| 52-Week Price Change | 2.7% |
| 50-Day Moving Average | 4.64 |
| 200-Day Moving Average | 5 |
| Relative Strength Index (RSI) | 36.79 |
| Average Volume (20 Days) | 161.77K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -62.38M |
| Net Income | -49.59M |
| EBITDA | -62.38M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.88 |
Balance Sheet
The company has 22.56M in cash and 1.53M in debt, giving a net cash position of 21.03M.
| Cash & Cash Equivalents | 22.56M |
| Total Debt | 1.53M |
| Net Cash | 21.03M |
| Retained Earnings | -227.21M |
| Total Assets | 252.09M |
| Working Capital | 239.58M |
Cash Flow
In the last 12 months, operating cash flow was -43.1M and capital expenditures -340K, giving a free cash flow of -43.45M.
| Operating Cash Flow | -43.1M |
| Capital Expenditures | -340K |
| Free Cash Flow | -43.45M |
| FCF Per Share | -0.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DSGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DSGN is $8, which is 110.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 110.5% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 11.04 |
| Piotroski F-Score | 2 |